[go: up one dir, main page]

WO1996009066A3 - Procede de traitement d'infections dues au virus de l'immunodeficience humaine (vih) - Google Patents

Procede de traitement d'infections dues au virus de l'immunodeficience humaine (vih) Download PDF

Info

Publication number
WO1996009066A3
WO1996009066A3 PCT/US1995/011943 US9511943W WO9609066A3 WO 1996009066 A3 WO1996009066 A3 WO 1996009066A3 US 9511943 W US9511943 W US 9511943W WO 9609066 A3 WO9609066 A3 WO 9609066A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
hiv
immunodeficiency virus
siv
treatment
Prior art date
Application number
PCT/US1995/011943
Other languages
English (en)
Other versions
WO1996009066A2 (fr
Inventor
Janice E Clements
Michael Murphey-Corb
M Christine Zink
Original Assignee
Univ Johns Hopkins Med
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Univ Tulane filed Critical Univ Johns Hopkins Med
Priority to EP95933167A priority Critical patent/EP0784484A2/fr
Priority to AU35930/95A priority patent/AU3593095A/en
Publication of WO1996009066A2 publication Critical patent/WO1996009066A2/fr
Publication of WO1996009066A3 publication Critical patent/WO1996009066A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un traitement prophylactique et curatif de l'infection causée chez un humain par le virus de l'immunodéficience humaine (VIH). Un modèle virus de l'immunodéficience de singe (VIS)-macaque montre que l'infection avec un VIS de recombinaison non pathogène mais visant les macrophages, assure une immunité systémique de l'hôte en stimulant la production d'anticorps neutralisants. Les essais montrent que les anticorps neutralisants produits ont une large réactivité vis-à-vis de plusieurs souches hétérologues de VIS. L'invention concerne également des compositions pharmaceutiques utiles pour le traitement d'un sujet avant ou après l'infection avec le VIH.
PCT/US1995/011943 1994-09-23 1995-09-19 Procede de traitement d'infections dues au virus de l'immunodeficience humaine (vih) WO1996009066A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95933167A EP0784484A2 (fr) 1994-09-23 1995-09-19 Procede de traitement d'infections dues au virus de l'immunodeficience humaine (vih)
AU35930/95A AU3593095A (en) 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31142494A 1994-09-23 1994-09-23
US08/311,424 1994-09-23

Publications (2)

Publication Number Publication Date
WO1996009066A2 WO1996009066A2 (fr) 1996-03-28
WO1996009066A3 true WO1996009066A3 (fr) 1996-05-23

Family

ID=23206813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011943 WO1996009066A2 (fr) 1994-09-23 1995-09-19 Procede de traitement d'infections dues au virus de l'immunodeficience humaine (vih)

Country Status (3)

Country Link
EP (1) EP0784484A2 (fr)
AU (1) AU3593095A (fr)
WO (1) WO1996009066A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (fr) * 1993-03-19 1994-09-29 Medical Research Council Systeme d'administration commande par des facteurs associes au vih et a la cellule

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (fr) * 1993-03-19 1994-09-29 Medical Research Council Systeme d'administration commande par des facteurs associes au vih et a la cellule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERNANDO PLATA ET AL.: "AIDS virus-specific cytotoxic T lymphocytes in lung disorders", NATURE, vol. 328, pages 348 - 351 *
JANICE E. CLEMENTS ET AL.: "Cross-Protective Immune Responses Induced in Rhesus Macaques by Immunization with Attenuated Macrophage-Tropic Simian Immunodeficiency Virus", JOURNAL OF VIROLOGY, vol. 69, no. 5, pages 2737 - 2744 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
EP0784484A2 (fr) 1997-07-23
AU3593095A (en) 1996-04-09
WO1996009066A2 (fr) 1996-03-28

Similar Documents

Publication Publication Date Title
DE3853779D1 (de) Hiv-1 neutralisierende monoklonale antikörper.
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
HK1051317A1 (zh) 新用途
ES548306A0 (es) Un procedimiento para transformar una cepa hospedante de le-vaduras del genero pichia
GR3023717T3 (en) Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.
IL91007A0 (en) Synthetic vaccine against aids virus
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
EP0272858A3 (fr) Protéines recombinantes d'enveloppe du HIV, produites dans des cellules d'insectes
AU1347688A (en) Viral antigen, process for its production, and application in diagnosis and therapy (vaccine)
EP0306219A3 (fr) Protéines et peptides du HIV pour le diagnostic, la prophylaxie et la thérapie du SIDA
WO1996009066A3 (fr) Procede de traitement d'infections dues au virus de l'immunodeficience humaine (vih)
AU1226288A (en) Processes for the preparation of medicinal compositions, compositions obtained by these processes and use thereof for the preparation of medicines against viral hepatitis b and acquired immunodeficiency syndrome
WO2022125378A8 (fr) Polythérapie
WO1990013281A3 (fr) Procede de suppression d'une infection par l'hiv
DE59814268D1 (de) Verfahren zur herstellung von ergosterol und dessen zwischenprodukten mittels rekombinanter hefen
EP4464380A3 (fr) Immunogènes vaccinaux contre le vih
DE69435142D1 (de) Methoden zur Inhibition von HIV-assoziierten Krankheiten mittels monoklonaler Antikörper gegen sich selbstgerichtete zytotoxische T-Zellen
EP0315459A3 (fr) Particules incomplètes du HIV et procédé pour leur préparation
AP9600896A0 (en) Anti-HIV triple combination.
EP0385909A3 (fr) Kit ou composition pour la prévention ou le traitement des infections par HIV-1
WO2003089000A3 (fr) Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4
EP0345028A3 (fr) Utilisation d'un inhibiteur de la phosphodiestérase pour le traitement du glaucome
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0235904A3 (fr) Traitement de l'allergie avec la thymopentine
NZ507942A (en) Viral chimeras comprised of CAEV and HIV-1 genetic elements

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995933167

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995933167

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995933167

Country of ref document: EP